A post-reaction regimen for CRC patients manifesting hypersensitivity to oxaliplatin : an effective alternative not to rule out an important option of treatment
C. Nisi(Arcispedale Sant'Anna), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Eri Banno(Arcispedale Sant'Anna), I. Carandina(Arcispedale Sant'Anna), A. Moretti(University of Ferrara), Lucia Da Ros(University of Ferrara), Donatella Donati(University of L'Aquila)
Cited by 1
Related Papers
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
|Annals of Oncology|2012|339
Adipose-Derived Mesenchymal Stem Cells as Stable Source of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery for Cancer Therapy
|Cancer Research|2010|244
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240